癌症患者的生育力保存:ASCO指南更新
该ASCO指南更新基于166项研究,为癌症患者提供生育力保存建议。推荐在诊断时及生存期评估并咨询生殖风险,有生育力保存意愿或不确定者应转诊生殖专家,并在抗癌治疗前讨论保存方法。男性应提供精子冷冻保存,青春期前男性睾丸组织冷冻保存仅限临床试验;女性应提供胚胎、卵母细胞、卵巢组织冷冻保存等成熟方法,GnRHa不应替代成熟方法但可用于乳腺癌辅助。
要点
- 癌症患者应在诊断时和生存期接受生殖风险评估与咨询,有生育力保存意愿或不确定者应转诊生殖专家。
- 男性抗癌治疗前应提供精子冷冻保存,无法提供精液样本者可行睾丸精子提取;青春期前睾丸组织冷冻保存仅限临床试验。
- 女性应提供胚胎、卵母细胞、卵巢组织冷冻保存等成熟方法;GnRHa不应替代成熟方法,但可作为乳腺癌女性辅助。
核心结论
- 癌症患者应在诊断时和生存期接受生殖风险评估与咨询,有生育力保存意愿或不确定者应转诊生殖专家,并在抗癌治疗前讨论生育力保存方法。
研究设计与样本
- ASCO召集多学科专家小组,更新系统综述,证据基础包括166项研究。
主要发现
- 男性抗癌治疗前应提供精子冷冻保存,无法提供精液样本时可行睾丸精子提取;青春期前男性睾丸组织冷冻保存为实验性,仅应在临床试验中提供。
- 女性应提供胚胎、卵母细胞和卵巢组织冷冻保存(OTC)、卵巢移位及保守性妇科手术等成熟生育力保存方法;卵母细胞体外成熟可作为新兴方法提供。
- 治疗后生育力保存可提供给未在治疗前进行生育力保存或未冷冻足够卵母细胞或胚胎者。
- GnRHa不应替代成熟生育力保存方法,但可作为乳腺癌女性的辅助治疗;因肿瘤急症需紧急抗癌治疗者,GnRHa可用于月经抑制。
- 已进入青春期的儿童应提供成熟生育力保存方法,需患者同意及父母/监护人知情同意;青春期前女性唯一成熟方法为OTC。
关键数值与推荐
- 男性抗癌治疗前应提供精子冷冻保存,无法提供精液样本时可行睾丸精子提取。
- 青春期前男性睾丸组织冷冻保存为实验性,仅应在临床试验中提供。
- 女性应提供胚胎、卵母细胞、卵巢组织冷冻保存(OTC)、卵巢移位及保守性妇科手术;卵母细胞体外成熟可作为新兴方法提供。
- GnRHa不应替代成熟生育力保存方法,但可作为乳腺癌女性的辅助治疗;肿瘤急症需紧急抗癌治疗时,GnRHa可用于月经抑制。
- 已进入青春期的儿童应提供成熟生育力保存方法,需患者同意及父母/监护人知情同意;青春期前女性唯一成熟方法为OTC。
临床怎么用
- 肿瘤团队应确保患者及时获得多学科生育力保存团队服务。
- 临床医生应倡导全面的生育力保存服务覆盖,并帮助患者获得相关福利。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide updated fertility preservation (FP) recommendations for people with cancer. METHODS: A multidisciplinary Expert Panel convened and updated the systematic review. RESULTS: One hundred sixty-six studies comprise the evidence base. RECOMMENDATIONS: People with cancer should be evaluated for and counseled about reproductive risks at diagnosis and during survivorship. Patients interested in or uncertain about FP should be referred to reproductive specialists. FP approaches should be discussed before cancer-directed therapy. Sperm cryopreservation should be offered to males before cancer-directed treatment, with testicular sperm extraction if unable to provide semen samples. Testicular tissue cryopreservation in prepubertal males is experimental and should be offered only in a clinical trial. Males should be advised of potentially higher genetic damage risks in sperm collected soon after cancer-directed therapy initiation and completion. For females, established FP methods should be offered, including embryo, oocyte, and ovarian tissue cryopreservation (OTC), ovarian transposition, and conservative gynecologic surgery. In vitro maturation of oocytes may be offered as an emerging method. Post-treatment FP may be offered to people who did not undergo pretreatment FP or cryopreserve enough oocytes or embryos. Gonadotropin-releasing hormone agonist (GnRHa) should not be used in place of established FP methods but may be offered as an adjunct to females with breast cancer. For patients with oncologic emergencies requiring urgent oncologic therapy, GnRHa may be offered for menstrual suppression. Established FP methods in children who have begun puberty should be offered with patient assent and parent/guardian consent. The only established method for prepubertal females is OTC. Oncology teams should ensure prompt access to a multidisciplinary FP team. Clinicians should advocate for comprehensive FP services coverage and help patients access benefits.Additional information is available at www.asco.org/survivorship-guidelines.
引用
- Su HI, Lacchetti C, Letourneau J, et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J Clin Oncol. 2025. PMID: 40106739. doi:10.1200/JCO-24-02782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。